Please login to the form below

Not currently logged in
Email:
Password:

amyloid

This page shows the latest amyloid news and features for those working in and with pharma, biotech and healthcare.

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb

continued uptake in the transthyretin amyloid cardiomyopathy indication in the US.

Latest news

More from news
Approximately 7 fully matching, plus 149 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    For amyloid plaques, it seems that these are more a consequence than a cause, which explains why no close correlation exists between amyloid load and cognitive function. ... Positron Emission Imaging (PET) – we can better select patients for either anti

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... other than the build-up of the hallmark Alzheimer’s proteins, amyloid and tau.

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    As important, the biomarker evidence supports the mechanism, with significant amyloid reduction leading to. ... A clutch of drugs with anti-amyloid mechanisms are in phase 2 and 3 trials.

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    The test works by identifying amyloid-beta (Abeta) proteins, which build up on the brains of those living with Alzheimer’s and which have a key link to the disease, although

  • A roadmap to the successful treatment of Alzheimer’s disease A roadmap to the successful treatment of Alzheimer’s disease

    plaques and oligomers formed by beta-amyloid occur outside the brain cells of people with Alzheimer’s. ... Firstly, it is now believed that treatments targeting beta-amyloid may only be effective before symptoms become apparent.

More from intelligence
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest appointments

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease. ... Alzheon's founder, president and chief executive officer Martin Tolar said: “JP will provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Alzheimer’s disease: reviewing the immediate treatment horizon

    Whilst there is increasing evidence that AD is a complex and multi-factorial disease, many scientists continue to believe that  beta-amyloid (Aβ)  is the main pathogenic factor responsible for the ... They represent an important shift of research

  • Forecasting in Forgotten Markets

    From a scientific perspective, the jury is still out on the root cause of these conditions and whether the current hypothesis around the involvement of Amyloid and Tau proteins in different

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...